Indian drugs group eyes $5 bn Swedish deal

May 31, 2013

Indian group Sun Pharmaceutical Industries is in talks to buy leading Swedish drugmaker Meda AB in what could result in a $5 billion takeover, the Wall Street Journal reported on Friday.

The US newspaper, citing anonymous sources, said Mumbai-based generic Sun Pharma was in talks with banks to finance the deal.

Sun Pharma, India's biggest pharmaceutical group by market capitalisation, with annual sales of more than $2 billion, is run and controlled by founder Dilip Shanghvi.

Meda, also a maker of branded generic prescription and over-the-counter drugs, is based in Stockholm and is listed on the Swedish stock exchange.

"Meda has a market value of roughly 25 billion kronor in Stockholm, meaning that with a typical takeover premium of 25 percent to 30 percent, it could be worth between $4.5 billion and $5 billion," the said.

Analysts say Meda, one of Sweden's largest pharmaceutical firms, is a desirable addition for any drugs company seeking to increase its pipeline of medicines in development.

Shares of Sun Pharma, which has a market capitalisation of nearly $20 billion—the highest of all Indian generics firms—closed down 2.54 percent at 1,045.5 rupees on Friday.

"We have no comment on media conjecture," a Sun spokeswoman told AFP.

Sun Pharma reported earlier in the week a 23.4 percent rise in quarterly net profit to 10.12 billion rupees, beating market estimates.

It took the company 27 years to cross the $1 billion mark but another 36 months to cross $2 billion, which it did in the last financial year.

Sun Pharma is among the most profitable drug companies in the world and its stock has gained over 35 percent so far in the year since January.

Sun Pharma last year acquired URL Pharma and DUSA Pharmaceuticals, both based in the United States. Its main US generics subsidiary is Caraco Pharmaceuticals, which is based in Detroit.

There has been that Sun Pharma may seek to strengthen its corporate portfolio with another high-profile acquisition.

Sun's founder Shanghvi said this week that the company, which already derives nearly three-quarters of its revenues from abroad, was focused on boosting its international presence.

Shanghvi founded Sun 30 years ago as a maker of psychiatric drugs.

Explore further: Royalty Pharma offers to buy Elan for about $6.5B (Update)

Related Stories

Royalty Pharma offers to buy Elan for about $6.5B (Update)

February 25, 2013
Royalty Pharma said Monday that it wants to buy Elan Corp. PLC for about $6.5 billion, but has yet to receive a formal response from the Irish drugmaker.

Elan moves to deter takeover bid

March 4, 2013
(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.

Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

April 11, 2013
Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

Actavis buying Warner Chilcott in $8.5B deal

May 20, 2013
Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the U.S. market.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.